U-RHHBY

Q:RHHBY - ROCHE HOLDINGS AG SPN ADR EACH REP 0.125 GENUS - http://roche.com

12:04:40 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
RHHBY - Q	not subscribed					31.37	+0.46	1.5	616.5	19,354	1,242	31.47 31.59 31.37	40.48 29.95	11:47:43	Apr 18	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTCQX International Premier -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 1242

More trades...

Time ET	Ex	Price	Change	Volume
11:47:43	Q	31.37	0.46	296
11:47:20	Q	31.37	0.46	460
11:47:19	Q	31.41	0.50	246
11:47:18	Q	31.41	0.50	250
11:47:18	Q	31.41	0.50	454
11:47:18	Q	31.41	0.50	200
11:47:13	Q	31.42	0.51	43
11:46:52	Q	31.41	0.50	1
11:46:52	Q	31.41	0.50	320
11:46:25	Q	31.415	0.505	684

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2024-04-18 16:35	U:RHHBY	News Release200	FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
2024-04-17 02:06	U:RHHBY	News Release200	Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
2024-04-15 01:10	U:RHHBY	News Release200	Genentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
2024-04-10 01:00	U:RHHBY	News Release200	Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Date ET

Symbol

Type

Headline

2024-04-18 16:35

U:RHHBY

News Release

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

2024-04-17 02:06

U:RHHBY

News Release

Genentech's Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS